Dyadic: Update on Phase 1 Trial for COVID-19 Recombinant Protein RBD Booster

 

• Dosing of all patients was completed at the end of February 

• No Serious Adverse Events (SAE’s) have been reported 

• Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 
  

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.

https://finance.yahoo.com/news/dyadic-provides-phase-1-clinical-133000683.html